206 related articles for article (PubMed ID: 29217620)
21. Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database.
Seror R; Lafourcade A; De Rycke Y; Pinto S; Castaneda J; Fautrel B; Mariette X; Tubach F
RMD Open; 2022 Jun; 8(2):. PubMed ID: 35738803
[TBL] [Abstract][Full Text] [Related]
22. Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study.
Westermann R; Cordtz RL; Duch K; Mellemkjaer L; Hetland ML; Burden AM; Dreyer L
Rheumatology (Oxford); 2024 Jan; 63(1):93-102. PubMed ID: 37052534
[TBL] [Abstract][Full Text] [Related]
23. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
Ramiro S; Gaujoux-Viala C; Nam JL; Smolen JS; Buch M; Gossec L; van der Heijde D; Winthrop K; Landewé R
Ann Rheum Dis; 2014 Mar; 73(3):529-35. PubMed ID: 24401994
[TBL] [Abstract][Full Text] [Related]
24. Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort.
Baganz L; Richter A; Kekow J; Bussmann A; Krause A; Stille C; Listing J; Zink A; Strangfeld A
Rheumatol Int; 2018 Apr; 38(4):579-587. PubMed ID: 29143933
[TBL] [Abstract][Full Text] [Related]
25. Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis.
Richter A; Listing J; Schneider M; Klopsch T; Kapelle A; Kaufmann J; Zink A; Strangfeld A
Ann Rheum Dis; 2016 Sep; 75(9):1667-73. PubMed ID: 26567181
[TBL] [Abstract][Full Text] [Related]
26. Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study.
Lampropoulos CE; Orfanos P; Bournia VK; Karatsourakis T; Mavragani C; Pikazis D; Manoussakis MN; Tzioufas AG; Moutsopoulos HM; Vlachoyiannopoulos PG
Clin Exp Rheumatol; 2015; 33(2):216-24. PubMed ID: 25664400
[TBL] [Abstract][Full Text] [Related]
27. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry.
Min HK; Kim HR; Lee SH; Shin K; Kim HA; Park SH; Kwok SK
Clin Rheumatol; 2021 Aug; 40(8):3105-3113. PubMed ID: 33576925
[TBL] [Abstract][Full Text] [Related]
28. Disease-modifying antirheumatic drugs and risk of thyroxine-treated autoimmune thyroid disease in patients with rheumatoid arthritis.
Waldenlind K; Delcoigne B; Saevarsdottir S; Askling J
J Intern Med; 2024 Mar; 295(3):313-321. PubMed ID: 37990795
[TBL] [Abstract][Full Text] [Related]
29. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.
Solomon DH; Kremer JM; Fisher M; Curtis JR; Furer V; Harrold LR; Hochberg MC; Reed G; Tsao P; Greenberg JD
Semin Arthritis Rheum; 2014 Feb; 43(4):489-97. PubMed ID: 24012043
[TBL] [Abstract][Full Text] [Related]
30. Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry.
Hetland ML; Jensen DV; Krogh NS
Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-141-6. PubMed ID: 25365104
[TBL] [Abstract][Full Text] [Related]
31. Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice.
Leon L; Gomez A; Vadillo C; Pato E; Rodriguez-Rodriguez L; Jover JA; Abasolo L
Clin Exp Rheumatol; 2018; 36(1):29-35. PubMed ID: 28598787
[TBL] [Abstract][Full Text] [Related]
32. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
Jones G; Hall S; Bird P; Littlejohn G; Tymms K; Youssef P; Chung E; Barrett R; Button P
Int J Rheum Dis; 2018 Aug; 21(8):1581-1590. PubMed ID: 29205926
[TBL] [Abstract][Full Text] [Related]
33. Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries.
Delcoigne B; Ljung L; Provan SA; Glintborg B; Hetland ML; Grøn KL; Peltomaa R; Relas H; Turesson C; Gudbjornsson B; Michelsen B; Askling J
Ann Rheum Dis; 2022 Jun; 81(6):789-797. PubMed ID: 35318218
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study.
Jinno S; Onishi A; Dubreuil M; Akashi K; Hashimoto M; Yamamoto W; Murata K; Takeuchi T; Kotani T; Maeda Y; Ebina K; Son Y; Amuro H; Hara R; Katayama M; Saegusa J; Morinobu A
Rheumatol Int; 2020 Dec; 40(12):1987-1995. PubMed ID: 32728836
[TBL] [Abstract][Full Text] [Related]
35. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
[TBL] [Abstract][Full Text] [Related]
36. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
Ramiro S; Sepriano A; Chatzidionysiou K; Nam JL; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; Bijlsma JW; Burmester GR; Scholte-Voshaar M; Falzon L; Landewé RBM
Ann Rheum Dis; 2017 Jun; 76(6):1101-1136. PubMed ID: 28298374
[TBL] [Abstract][Full Text] [Related]
37. Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria.
Rintelen B; Zwerina J; Herold M; Singer F; Hitzelhammer J; Halder W; Eichbauer-Sturm G; Puchner R; Stetter M; Leeb BF;
BMC Musculoskelet Disord; 2016 Aug; 17(1):358. PubMed ID: 27550175
[TBL] [Abstract][Full Text] [Related]
38. Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.
Gerhold K; Richter A; Schneider M; Bergerhausen HJ; Demary W; Liebhaber A; Listing J; Zink A; Strangfeld A
Rheumatology (Oxford); 2015 Oct; 54(10):1858-66. PubMed ID: 26001633
[TBL] [Abstract][Full Text] [Related]
39. Clinical Characteristics and Cytokine Profiles of Organizing Pneumonia in Patients with Rheumatoid Arthritis Treated with or without Biologics.
Kawasumi H; Gono T; Tanaka E; Kaneko H; Kawaguchi Y; Yamanaka H
J Rheumatol; 2016 Apr; 43(4):738-44. PubMed ID: 26834212
[TBL] [Abstract][Full Text] [Related]
40. Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.
Kalkan A; Husberg M; Hallert E; Roback K; Thyberg I; Skogh T; Carlsson P
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1679-85. PubMed ID: 26097219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
